Related Experiment Video
Updated: Apr 7, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Erdafitinib-Induced Flexural Calcinosis Cutis in a Pediatric Patient: A Drug-Specific Side-Effect?
Sara de Benito-Mendieta1, Susana Buendía2, Lucero Noguera-Morel1
1Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Abstract:
Fibroblast growth factor receptor (FGFR) inhibitors are effective in malignancies with FGFR pathway alterations but may disrupt calcium-phosphate metabolism, leading to dermatologic side effects. We report a case of calcinosis cutis presenting as painful flexural plaques in a 16-year-old patient treated with erdafitinib for high-grade glioma. The patient's age, unusual lesion distribution, and spontaneous resolution after drug discontinuation highlight a previously unreported association in pediatrics. Recognizing this potential adverse effect may help avoid unnecessary diagnostic or therapeutic interventions.
Insights
Fibroblast growth factor receptor (FGFR) inhibitors can cause skin issues. A case study shows calcinosis cutis in a pediatric patient treated with erdafitinib, highlighting a new side effect in children.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Fibroblast growth factor receptor (FGFR) inhibitors are crucial in treating malignancies with specific genetic alterations.
- These targeted therapies can disrupt calcium-phosphate metabolism, potentially causing dermatologic adverse events.
- Calcinosis cutis is a rare condition characterized by calcium salt deposition in the skin.
